Autolus Therapeutics plc AUTL

Healthcare Biotechnology

Autolus Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. It is focused on chimeric antigen receptor (CAR)-T cell therapy. Using a suite of proprietary and modular T cell programming technologies, it is engineering targeted, controlled and highly active T cell therapy product candidates that are designed to recognize target cells, break down their defense mechanisms and eliminate these cells. It has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. Its products pipeline includes obe-cel (FELIX), obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting T Cell Receptor Beta Constant (TRBC) 1 and TRBC 2.

NDAQ:AUTL - Post by User

Autolus Therapeutics plc

Bullboard Posts

Next >>

Post by coolfooldumbguyon Sep 06, 2019 12:02pm

119 Views

Post# 30102614

it's a buy today for me

at bout 15 U.S.per share it is worth my money,it should be a triple for me as my target price is about $45 U.S. per share,so glta,but my profits from PDD are paying this one for me,so it's free for me.

Bullboard Posts

Next >>

One of the strongest contenders to lead Canada’s cannabis market